MA51915A - Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna) - Google Patents
Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)Info
- Publication number
- MA51915A MA51915A MA051915A MA51915A MA51915A MA 51915 A MA51915 A MA 51915A MA 051915 A MA051915 A MA 051915A MA 51915 A MA51915 A MA 51915A MA 51915 A MA51915 A MA 51915A
- Authority
- MA
- Morocco
- Prior art keywords
- cedna
- transgenes
- closed
- regulated expression
- dna vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862633757P | 2018-02-22 | 2018-02-22 | |
US201862633795P | 2018-02-22 | 2018-02-22 | |
US201862633882P | 2018-02-22 | 2018-02-22 | |
US201862746762P | 2018-10-17 | 2018-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51915A true MA51915A (fr) | 2020-12-30 |
Family
ID=67687406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051915A MA51915A (fr) | 2018-02-22 | 2019-02-21 | Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna) |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220175970A1 (fr) |
EP (1) | EP3755803A4 (fr) |
JP (2) | JP2021513999A (fr) |
KR (1) | KR20200124250A (fr) |
CN (1) | CN111886343A (fr) |
AU (1) | AU2019225937A1 (fr) |
BR (1) | BR112020017060A2 (fr) |
CA (1) | CA3092059A1 (fr) |
IL (1) | IL276658A (fr) |
MA (1) | MA51915A (fr) |
MX (1) | MX2020008676A (fr) |
SG (1) | SG11202007621TA (fr) |
WO (1) | WO2019165050A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3877528A4 (fr) * | 2018-11-09 | 2022-11-30 | Generation Bio Co. | Adn à extrémité fermée modifié (cedna) comprenant des répétitions terminales inversées modifiées symétriques |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
US20230138409A1 (en) * | 2020-03-24 | 2023-05-04 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
US20230134550A1 (en) * | 2020-03-24 | 2023-05-04 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
JP2023524010A (ja) * | 2020-04-28 | 2023-06-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 高効率遺伝子送達系 |
IL299422A (en) * | 2020-06-26 | 2023-02-01 | Univ Leland Stanford Junior | Targeting the human CCR5 locus as a safe site for the expression of therapeutic proteins |
WO2022023284A1 (fr) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation |
CN116194152A (zh) * | 2020-08-23 | 2023-05-30 | 比奥维拉迪维治疗股份有限公司 | 用于改进封闭端DNA(ceDNA)的产生的经修饰的杆状病毒系统 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003087334A2 (fr) * | 2002-04-09 | 2003-10-23 | Cornell Research Foundation, Inc. | Utilisation d'element d'efficacite d'integration de virus adeno-associe (aav) permettant d'assurer la mediation d'une integration specifique de site d'une unite de transcription |
DK2816118T3 (en) * | 2005-05-31 | 2018-12-03 | Univ Colorado Regents | Methods for delivery of genes |
WO2009038462A1 (fr) * | 2007-09-19 | 2009-03-26 | Amsterdam Molecular Therapeutics B.V. | Utilisation de la machinerie de réplication d'un virus adéno-associé (aav) pour une production protéique améliorée |
EP2500434A1 (fr) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique |
WO2015191508A1 (fr) * | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Capsides chimériques |
CA2957737A1 (fr) * | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Procedes et compositions pour attenuer des reponses immunitaires contre des vecteurs de transfert viraux modulant l'expression genique |
EP3230451B1 (fr) * | 2014-12-12 | 2021-04-07 | The Broad Institute, Inc. | Arn guides protégés (pgrnas) |
CN109195636B (zh) * | 2016-03-03 | 2022-07-05 | 马萨诸塞大学 | 用于非病毒基因转移的末端封闭型线性双链体dna |
-
2019
- 2019-02-21 US US16/971,016 patent/US20220175970A1/en active Pending
- 2019-02-21 KR KR1020207026566A patent/KR20200124250A/ko unknown
- 2019-02-21 BR BR112020017060-7A patent/BR112020017060A2/pt unknown
- 2019-02-21 EP EP19757005.4A patent/EP3755803A4/fr active Pending
- 2019-02-21 MX MX2020008676A patent/MX2020008676A/es unknown
- 2019-02-21 CN CN201980019861.5A patent/CN111886343A/zh active Pending
- 2019-02-21 AU AU2019225937A patent/AU2019225937A1/en active Pending
- 2019-02-21 WO PCT/US2019/018927 patent/WO2019165050A1/fr active Application Filing
- 2019-02-21 SG SG11202007621TA patent/SG11202007621TA/en unknown
- 2019-02-21 JP JP2020544445A patent/JP2021513999A/ja active Pending
- 2019-02-21 MA MA051915A patent/MA51915A/fr unknown
- 2019-02-21 CA CA3092059A patent/CA3092059A1/fr active Pending
-
2020
- 2020-08-11 IL IL276658A patent/IL276658A/en unknown
-
2023
- 2023-12-08 JP JP2023207938A patent/JP2024028931A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3092059A1 (fr) | 2019-08-29 |
US20220175970A1 (en) | 2022-06-09 |
IL276658A (en) | 2020-09-30 |
WO2019165050A1 (fr) | 2019-08-29 |
RU2020131041A (ru) | 2022-03-22 |
CN111886343A (zh) | 2020-11-03 |
BR112020017060A2 (pt) | 2020-12-15 |
KR20200124250A (ko) | 2020-11-02 |
AU2019225937A1 (en) | 2020-08-13 |
JP2024028931A (ja) | 2024-03-05 |
EP3755803A4 (fr) | 2022-01-19 |
MX2020008676A (es) | 2020-09-25 |
EP3755803A1 (fr) | 2020-12-30 |
JP2021513999A (ja) | 2021-06-03 |
SG11202007621TA (en) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51915A (fr) | Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna) | |
MA51113A (fr) | Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce) | |
MA51644A (fr) | Méthodes d'évaluation de la capacité de transduction de vecteurs viraux | |
MA50942A (fr) | Protéines de liaison à l'adn modifiées | |
CA200053S (fr) | Boucle d'oreille | |
MA49421A (fr) | Formulations d'arn | |
MA49913A (fr) | Variants d'arn polymérase | |
DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
MA51619A (fr) | Inhibiteurs de la protéine kinase dépendante de l'adn | |
CA189234S (fr) | Boucle d'oreille | |
MA49513A (fr) | Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines | |
MA43817A (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
MA54958A (fr) | Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée | |
FR3056393B1 (fr) | Orthese d'extension de machoires | |
CA189957S (fr) | Boucle d'oreille | |
MA44976A (fr) | Sélection directe de cellules exprimant des teneurs élevées en protéines hétéromères à l'aide de vecteurs de complémentation intragénique de glutamine synthétase | |
MA46523A (fr) | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 | |
MA50369A (fr) | Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament | |
MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
CA185201S (fr) | Boucle d'oreilles | |
MA53548A (fr) | Formulations antiparasitaires de goût agréable | |
MA46750A (fr) | Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents | |
DK3999119T3 (da) | Modificerede AVV-capsidproteiner til behandling af slidgigtsygdom | |
CA189215S (fr) | Boucle d'oreille | |
IL281720A (en) | HMGB1 protein derivatives to remove biofilms |